Loading…
Sphingolipidomics analysis of large clinical cohorts. Part 2: Potential impact and applications
It has been known for decades that the regulation of sphingolipids (SLs) is essential for the proper function of many cellular processes. However, a complete understanding of these processes has been complicated by the structural diversity of these lipids. A well-characterized metabolic pathway is r...
Saved in:
Published in: | Biochemical and biophysical research communications 2018-10, Vol.504 (3), p.602-607 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c384t-e0a4943a5fff294b9cdb09cd4404423cfcdc4eca785d98b7d0c45ad392a2aa913 |
---|---|
cites | cdi_FETCH-LOGICAL-c384t-e0a4943a5fff294b9cdb09cd4404423cfcdc4eca785d98b7d0c45ad392a2aa913 |
container_end_page | 607 |
container_issue | 3 |
container_start_page | 602 |
container_title | Biochemical and biophysical research communications |
container_volume | 504 |
creator | Chong, Joyce R. Xiang, Ping Wang, Wei Hind, Tatsuma Chew, Wee Siong Ong, Wei-Yi Lai, Mitchell K.P. Herr, Deron R. |
description | It has been known for decades that the regulation of sphingolipids (SLs) is essential for the proper function of many cellular processes. However, a complete understanding of these processes has been complicated by the structural diversity of these lipids. A well-characterized metabolic pathway is responsible for homeostatic maintenance of hundreds of distinct SL species. This pathway is perturbed in a number of pathological processes, resulting in derangement of the “sphingolipidome.” Recently, advances in mass spectrometry (MS) techniques have made it possible to characterize the sphingolipidome in large-scale clinical studies, allowing for the identification of specific SL molecules that mediate pathological processes and/or may serve as biomarkers. This manuscript provides an overview of the functions of SLs, and reviews previous studies that have used MS techniques to identify changes to the sphingolipidome in non-metabolic diseases.
•Sphingolipids have diverse biological roles in essentially every eukaryotic cell.•An understanding of these roles is improving due to advances in mass spectrometry.•Resulting sphingolipidomic profiles are becoming increasingly detailed.•This improves our understanding of disease and identifies potential biomarkers.•This review discusses biomedical applications of sphingolipidomics. |
doi_str_mv | 10.1016/j.bbrc.2018.04.075 |
format | article |
fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_23134191</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006291X18308441</els_id><sourcerecordid>2025320156</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-e0a4943a5fff294b9cdb09cd4404423cfcdc4eca785d98b7d0c45ad392a2aa913</originalsourceid><addsrcrecordid>eNp9kE2LFDEQhoMo7rj6BzxIwIuXbivpdPdEvMjiFyy4oIK3kK6kdzKkkzbJCPvvTTurRy9Vh3rel-Ih5DmDlgEbXh_baUrYcmD7FkQLY_-A7BhIaDgD8ZDsAGBouGQ_LsiTnI8AjIlBPiYXXA69GPtxR9TX9eDCbfRudSYuDjPVQfu77DKNM_U63VqK3gWH2lOMh5hKbumNToXyN_QmFhuKqye3rBpLDRuq19VXvLgY8lPyaNY-22f3-5J8__D-29Wn5vrLx89X764b7PaiNBa0kKLT_TzPXIpJopmgDiFACN7hjAaFRT3ueyP302gARa9NJ7nmWkvWXZKX596Yi1MZXbF4wBiCxaJ4xzrB_lCvztSa4s-TzUUtLqP1XgcbT1lx4H1XffZDRfkZxRRzTnZWa3KLTneKgdr0q6Pa9KtNvwKhqv4aenHff5oWa_5F_vquwNszYKuLX86m7VUb0BqXtk9NdP_r_w06RZcD</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2025320156</pqid></control><display><type>article</type><title>Sphingolipidomics analysis of large clinical cohorts. Part 2: Potential impact and applications</title><source>ScienceDirect Journals</source><creator>Chong, Joyce R. ; Xiang, Ping ; Wang, Wei ; Hind, Tatsuma ; Chew, Wee Siong ; Ong, Wei-Yi ; Lai, Mitchell K.P. ; Herr, Deron R.</creator><creatorcontrib>Chong, Joyce R. ; Xiang, Ping ; Wang, Wei ; Hind, Tatsuma ; Chew, Wee Siong ; Ong, Wei-Yi ; Lai, Mitchell K.P. ; Herr, Deron R.</creatorcontrib><description>It has been known for decades that the regulation of sphingolipids (SLs) is essential for the proper function of many cellular processes. However, a complete understanding of these processes has been complicated by the structural diversity of these lipids. A well-characterized metabolic pathway is responsible for homeostatic maintenance of hundreds of distinct SL species. This pathway is perturbed in a number of pathological processes, resulting in derangement of the “sphingolipidome.” Recently, advances in mass spectrometry (MS) techniques have made it possible to characterize the sphingolipidome in large-scale clinical studies, allowing for the identification of specific SL molecules that mediate pathological processes and/or may serve as biomarkers. This manuscript provides an overview of the functions of SLs, and reviews previous studies that have used MS techniques to identify changes to the sphingolipidome in non-metabolic diseases.
•Sphingolipids have diverse biological roles in essentially every eukaryotic cell.•An understanding of these roles is improving due to advances in mass spectrometry.•Resulting sphingolipidomic profiles are becoming increasingly detailed.•This improves our understanding of disease and identifies potential biomarkers.•This review discusses biomedical applications of sphingolipidomics.</description><identifier>ISSN: 0006-291X</identifier><identifier>EISSN: 1090-2104</identifier><identifier>DOI: 10.1016/j.bbrc.2018.04.075</identifier><identifier>PMID: 29654757</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>60 APPLIED LIFE SCIENCES ; Autoimmune disease ; BIOLOGICAL MARKERS ; BIOLOGICAL PATHWAYS ; Cancer ; Ceramide ; Dementia ; Lipidomics ; METABOLIC DISEASES ; NEOPLASMS ; NERVOUS SYSTEM DISEASES ; Neutral sphingomyelinase 2 (nSMase2) ; Sphingolipid ; Sphingomyelin ; Sphingomyelinase ; SPHINGOMYELINS ; Sphingosine-1-phosphate ; Stroke</subject><ispartof>Biochemical and biophysical research communications, 2018-10, Vol.504 (3), p.602-607</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright © 2018 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-e0a4943a5fff294b9cdb09cd4404423cfcdc4eca785d98b7d0c45ad392a2aa913</citedby><cites>FETCH-LOGICAL-c384t-e0a4943a5fff294b9cdb09cd4404423cfcdc4eca785d98b7d0c45ad392a2aa913</cites><orcidid>0000-0002-8648-9665 ; 0000-0001-5755-0896</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29654757$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/23134191$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Chong, Joyce R.</creatorcontrib><creatorcontrib>Xiang, Ping</creatorcontrib><creatorcontrib>Wang, Wei</creatorcontrib><creatorcontrib>Hind, Tatsuma</creatorcontrib><creatorcontrib>Chew, Wee Siong</creatorcontrib><creatorcontrib>Ong, Wei-Yi</creatorcontrib><creatorcontrib>Lai, Mitchell K.P.</creatorcontrib><creatorcontrib>Herr, Deron R.</creatorcontrib><title>Sphingolipidomics analysis of large clinical cohorts. Part 2: Potential impact and applications</title><title>Biochemical and biophysical research communications</title><addtitle>Biochem Biophys Res Commun</addtitle><description>It has been known for decades that the regulation of sphingolipids (SLs) is essential for the proper function of many cellular processes. However, a complete understanding of these processes has been complicated by the structural diversity of these lipids. A well-characterized metabolic pathway is responsible for homeostatic maintenance of hundreds of distinct SL species. This pathway is perturbed in a number of pathological processes, resulting in derangement of the “sphingolipidome.” Recently, advances in mass spectrometry (MS) techniques have made it possible to characterize the sphingolipidome in large-scale clinical studies, allowing for the identification of specific SL molecules that mediate pathological processes and/or may serve as biomarkers. This manuscript provides an overview of the functions of SLs, and reviews previous studies that have used MS techniques to identify changes to the sphingolipidome in non-metabolic diseases.
•Sphingolipids have diverse biological roles in essentially every eukaryotic cell.•An understanding of these roles is improving due to advances in mass spectrometry.•Resulting sphingolipidomic profiles are becoming increasingly detailed.•This improves our understanding of disease and identifies potential biomarkers.•This review discusses biomedical applications of sphingolipidomics.</description><subject>60 APPLIED LIFE SCIENCES</subject><subject>Autoimmune disease</subject><subject>BIOLOGICAL MARKERS</subject><subject>BIOLOGICAL PATHWAYS</subject><subject>Cancer</subject><subject>Ceramide</subject><subject>Dementia</subject><subject>Lipidomics</subject><subject>METABOLIC DISEASES</subject><subject>NEOPLASMS</subject><subject>NERVOUS SYSTEM DISEASES</subject><subject>Neutral sphingomyelinase 2 (nSMase2)</subject><subject>Sphingolipid</subject><subject>Sphingomyelin</subject><subject>Sphingomyelinase</subject><subject>SPHINGOMYELINS</subject><subject>Sphingosine-1-phosphate</subject><subject>Stroke</subject><issn>0006-291X</issn><issn>1090-2104</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kE2LFDEQhoMo7rj6BzxIwIuXbivpdPdEvMjiFyy4oIK3kK6kdzKkkzbJCPvvTTurRy9Vh3rel-Ih5DmDlgEbXh_baUrYcmD7FkQLY_-A7BhIaDgD8ZDsAGBouGQ_LsiTnI8AjIlBPiYXXA69GPtxR9TX9eDCbfRudSYuDjPVQfu77DKNM_U63VqK3gWH2lOMh5hKbumNToXyN_QmFhuKqye3rBpLDRuq19VXvLgY8lPyaNY-22f3-5J8__D-29Wn5vrLx89X764b7PaiNBa0kKLT_TzPXIpJopmgDiFACN7hjAaFRT3ueyP302gARa9NJ7nmWkvWXZKX596Yi1MZXbF4wBiCxaJ4xzrB_lCvztSa4s-TzUUtLqP1XgcbT1lx4H1XffZDRfkZxRRzTnZWa3KLTneKgdr0q6Pa9KtNvwKhqv4aenHff5oWa_5F_vquwNszYKuLX86m7VUb0BqXtk9NdP_r_w06RZcD</recordid><startdate>20181007</startdate><enddate>20181007</enddate><creator>Chong, Joyce R.</creator><creator>Xiang, Ping</creator><creator>Wang, Wei</creator><creator>Hind, Tatsuma</creator><creator>Chew, Wee Siong</creator><creator>Ong, Wei-Yi</creator><creator>Lai, Mitchell K.P.</creator><creator>Herr, Deron R.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>OTOTI</scope><orcidid>https://orcid.org/0000-0002-8648-9665</orcidid><orcidid>https://orcid.org/0000-0001-5755-0896</orcidid></search><sort><creationdate>20181007</creationdate><title>Sphingolipidomics analysis of large clinical cohorts. Part 2: Potential impact and applications</title><author>Chong, Joyce R. ; Xiang, Ping ; Wang, Wei ; Hind, Tatsuma ; Chew, Wee Siong ; Ong, Wei-Yi ; Lai, Mitchell K.P. ; Herr, Deron R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-e0a4943a5fff294b9cdb09cd4404423cfcdc4eca785d98b7d0c45ad392a2aa913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>60 APPLIED LIFE SCIENCES</topic><topic>Autoimmune disease</topic><topic>BIOLOGICAL MARKERS</topic><topic>BIOLOGICAL PATHWAYS</topic><topic>Cancer</topic><topic>Ceramide</topic><topic>Dementia</topic><topic>Lipidomics</topic><topic>METABOLIC DISEASES</topic><topic>NEOPLASMS</topic><topic>NERVOUS SYSTEM DISEASES</topic><topic>Neutral sphingomyelinase 2 (nSMase2)</topic><topic>Sphingolipid</topic><topic>Sphingomyelin</topic><topic>Sphingomyelinase</topic><topic>SPHINGOMYELINS</topic><topic>Sphingosine-1-phosphate</topic><topic>Stroke</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chong, Joyce R.</creatorcontrib><creatorcontrib>Xiang, Ping</creatorcontrib><creatorcontrib>Wang, Wei</creatorcontrib><creatorcontrib>Hind, Tatsuma</creatorcontrib><creatorcontrib>Chew, Wee Siong</creatorcontrib><creatorcontrib>Ong, Wei-Yi</creatorcontrib><creatorcontrib>Lai, Mitchell K.P.</creatorcontrib><creatorcontrib>Herr, Deron R.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><jtitle>Biochemical and biophysical research communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chong, Joyce R.</au><au>Xiang, Ping</au><au>Wang, Wei</au><au>Hind, Tatsuma</au><au>Chew, Wee Siong</au><au>Ong, Wei-Yi</au><au>Lai, Mitchell K.P.</au><au>Herr, Deron R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sphingolipidomics analysis of large clinical cohorts. Part 2: Potential impact and applications</atitle><jtitle>Biochemical and biophysical research communications</jtitle><addtitle>Biochem Biophys Res Commun</addtitle><date>2018-10-07</date><risdate>2018</risdate><volume>504</volume><issue>3</issue><spage>602</spage><epage>607</epage><pages>602-607</pages><issn>0006-291X</issn><eissn>1090-2104</eissn><abstract>It has been known for decades that the regulation of sphingolipids (SLs) is essential for the proper function of many cellular processes. However, a complete understanding of these processes has been complicated by the structural diversity of these lipids. A well-characterized metabolic pathway is responsible for homeostatic maintenance of hundreds of distinct SL species. This pathway is perturbed in a number of pathological processes, resulting in derangement of the “sphingolipidome.” Recently, advances in mass spectrometry (MS) techniques have made it possible to characterize the sphingolipidome in large-scale clinical studies, allowing for the identification of specific SL molecules that mediate pathological processes and/or may serve as biomarkers. This manuscript provides an overview of the functions of SLs, and reviews previous studies that have used MS techniques to identify changes to the sphingolipidome in non-metabolic diseases.
•Sphingolipids have diverse biological roles in essentially every eukaryotic cell.•An understanding of these roles is improving due to advances in mass spectrometry.•Resulting sphingolipidomic profiles are becoming increasingly detailed.•This improves our understanding of disease and identifies potential biomarkers.•This review discusses biomedical applications of sphingolipidomics.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29654757</pmid><doi>10.1016/j.bbrc.2018.04.075</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-8648-9665</orcidid><orcidid>https://orcid.org/0000-0001-5755-0896</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-291X |
ispartof | Biochemical and biophysical research communications, 2018-10, Vol.504 (3), p.602-607 |
issn | 0006-291X 1090-2104 |
language | eng |
recordid | cdi_osti_scitechconnect_23134191 |
source | ScienceDirect Journals |
subjects | 60 APPLIED LIFE SCIENCES Autoimmune disease BIOLOGICAL MARKERS BIOLOGICAL PATHWAYS Cancer Ceramide Dementia Lipidomics METABOLIC DISEASES NEOPLASMS NERVOUS SYSTEM DISEASES Neutral sphingomyelinase 2 (nSMase2) Sphingolipid Sphingomyelin Sphingomyelinase SPHINGOMYELINS Sphingosine-1-phosphate Stroke |
title | Sphingolipidomics analysis of large clinical cohorts. Part 2: Potential impact and applications |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T21%3A32%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sphingolipidomics%20analysis%20of%20large%20clinical%20cohorts.%20Part%202:%20Potential%20impact%20and%20applications&rft.jtitle=Biochemical%20and%20biophysical%20research%20communications&rft.au=Chong,%20Joyce%20R.&rft.date=2018-10-07&rft.volume=504&rft.issue=3&rft.spage=602&rft.epage=607&rft.pages=602-607&rft.issn=0006-291X&rft.eissn=1090-2104&rft_id=info:doi/10.1016/j.bbrc.2018.04.075&rft_dat=%3Cproquest_osti_%3E2025320156%3C/proquest_osti_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c384t-e0a4943a5fff294b9cdb09cd4404423cfcdc4eca785d98b7d0c45ad392a2aa913%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2025320156&rft_id=info:pmid/29654757&rfr_iscdi=true |